Synergistic Cellular and Biotherapeutic Agent Delivery System

Publication ID: 24-11857673_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Cellular and Biotherapeutic Agent Delivery System,” Published Technical Disclosure No. 24-11857673_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857673_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,673.

Summary of the Inventive Concept

A novel system integrating nanoporous materials with AI, IoT, blockchain, and new materials to create a more powerful, personalized, and secure cellular and biotherapeutic agent delivery platform.

Background and Problem Solved

The original patent provided a foundational invention for implantable cellular and biotherapeutic agent delivery canisters. However, it lacked the capabilities for real-time monitoring, personalized treatment, and secure tracking. The new inventive concept addresses these limitations by synergistically combining the nanoporous material with distinct technologies to create a more comprehensive and effective system.

Detailed Description of the Inventive Concept

The synergistic system comprises an implantable canister with a nanoporous material, an IoT sensor for real-time monitoring, an AI-powered diagnostic system for personalized treatment, and a blockchain-based platform for secure tracking. The hybrid material integrates a nanoporous metal matrix with a biocompatible polymer and a conductive material for enhanced sensing and monitoring capabilities. The system enables remote monitoring and control, predictive analytics, and real-time adjustments to delivery parameters.

Novelty and Inventive Step

The new claims introduce a novel combination of technologies that provides a more powerful and comprehensive system for cellular and biotherapeutic agent delivery. The inventive step lies in the synergistic integration of AI, IoT, blockchain, and new materials with the nanoporous material, enabling real-time monitoring, personalized treatment, and secure tracking.

Alternative Embodiments and Variations

Alternative embodiments may include varying the type of IoT sensor, AI algorithm, or blockchain platform used. Additionally, the hybrid material could be modified to incorporate different biocompatible polymers or conductive materials. The system could also be adapted for use in various medical applications, such as cancer treatment or regenerative medicine.

Potential Commercial Applications and Market

The synergistic cellular and biotherapeutic agent delivery system has significant commercial potential in the pharmaceutical, biotechnology, and medical device industries. Target markets include companies developing personalized medicine solutions, IoT-enabled healthcare devices, and secure data management platforms for healthcare applications.

CPC Classifications

Section	Class	Group
A	A61	A61K9/0024
A	A61	A61F2/022
A	A61	A61K31/337
A	A61	A61K31/397
A	A61	A61K31/436
A	A61	A61K31/65
A	A61	A61K31/7036
A	A61	A61K35/28
A	A61	A61K38/14
A	A61	A61K38/1866
A	A61	A61K38/22
A	A61	A61K39/395
A	A61	A61K47/02
A	A61	A61M39/0247
A	A61	A61M2039/027
A	A61	A61M2039/0261
A	A61	A61M2039/0276
A	A61	A61M2205/04

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biomedical device engineering with specialization in implantable drug delivery systems, nanomaterials, and medical sensor technologies. Requires advanced degrees in bioengineering, materials science, or related interdisciplinary fields with expertise in nanotechnology and medical device design

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced technical knowledge of nanoporous materials, medical device integration, sensor technologies, and biocompatible system design. Capable of understanding complex interdisciplinary technological combinations and recognizing incremental innovations

Obviousness Rationale

A PHOSITA would recognize that integrating IoT, AI, and blockchain technologies with existing nanoporous implantable delivery systems represents a predictable technological evolution. The source patent's foundational nanoporous capsule design provides a clear technical framework for expanding monitoring and personalization capabilities. The proposed variations represent logical extensions of existing medical device integration strategies using well-established technological components.

Obvious Combinations & Variations

Source Patent Element

Apertured metallic capsule with nanophase tubular structure for cellular agent delivery

PTD Variation

Adding IoT sensor integration for real-time monitoring and tracking of delivery metrics

Obviousness Reasoning

Adding sensor monitoring to an existing medical device is a known technique in medical technology, representing a predictable improvement in device functionality

Source Patent Element

Nanoporous metallic substrate with nanotubes facilitating fluid exchange

PTD Variation

Incorporating biocompatible polymer and conductive materials to enhance sensing capabilities

Obviousness Reasoning

Material modification to improve device performance is a standard design approach in medical device engineering, with finite and predictable optimization strategies

Source Patent Element

Implantable medical device for cellular and biotherapeutic agent delivery

PTD Variation

Implementing AI-powered diagnostic system for personalized treatment optimization

Obviousness Reasoning

Applying machine learning and data analytics to medical device functionality represents an obvious technological progression in precision medicine

Source Patent Element

Metallic capsule with nanoporous structure

PTD Variation

Blockchain-based secure tracking platform for delivery monitoring

Obviousness Reasoning

Implementing secure digital tracking mechanisms is a known solution for improving medical device data management and patient safety

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857673 and the disclosed technological variations, a person having ordinary skill in the art would find the proposed cellular and biotherapeutic agent delivery system variations obvious and non-patentable. The incremental technological additions represent predictable combinations of known medical device design strategies that would be readily conceived by a skilled practitioner in the field of implantable medical technologies.

Original Patent Information

Patent Number	US 11,857,673
Title	Implantable cellular and biotherapeutic agent delivery canister
Assignee(s)	NanoVault Medical LLC